FIG. 30:  Another agent in the treatment of NMI bladder cancer is Mycobacterium phlei cell wall-nucleic acid complex (MCNA).   A Phase 2 open-label study of MCNA in 129 patients included all patients who had failed BCG.^[27]  Among the BCG-unresponsive population, however, in a subgroup of 94 patients the overall 1-year disease-free survival (CR rate) was 34.8%.  For CIS patients with/without papillary disease, disease-free survival at 1 year was 23.5%, and for patients with papillary only tumors, it was 61.2% at 1 year.